Table 1.
Baseline characteristics of eligible clinical trials
| Author (Year) | Design | Inclusion criteria | Number of eyes | Sex (M/F) | Age (year) | Models of AGV | Models of BGI | IOP (mmHg) Standards of Success | Follow-up duration (months) | Baseline IOP (mmHg) |
|---|---|---|---|---|---|---|---|---|---|---|
| Budenz DL (2015) | RCT | >18y | A:143 | A:73/70 | A:65.4 ± 12.8 | FP7 | 350 | 5≤ IOP ≤21 and ≥20 % reduction | 60 | A:31.2 ± 11.2 |
| B:133 | B:70/63 | B:62.2 ± 14.2 | B:31.8 ± 12.5 | |||||||
| Christakis PG (2013) | RCT | >18y | A:124 | A:65/59 | A:65 ± 17 | FP7 | 350 | 5≤ IOP ≤21* and ≥20 % reduction | 36 | A:31.1 ± 10.5 |
| B:114 | B:41/73 | B:67 ± 15 | B:31.7 ± 11.1 | |||||||
| El Gendy NM (2012) | Retro | <18y | A:11 | A:4/7 | A:6.7 | S2 | 250 | 8≤ IOP ≤24 | A:32.4 | A:39.8 ± 6.2 |
| B:20 | B:12/8 | B:5.4 | B:45.6 | B:33.8 ± 5.7 | ||||||
| Goulet RJ (2008) | Retro | All ages | A:59 | A:25/34 | A:66.3 ± 15.14 | S2 | 250 | 5< IOP <22 and ≥20 % reduction | A:20.0 ± 26.7 | A:35.3 ± 13.4 |
| B:133 | B:64/69 | B:64.3 ± 16.9 | B:22.9 ± 19.9 | B:35.3 ± 12.9 | ||||||
| Tsai JC (2006) | Retro | >18y | A:48 | A:18/30 | A:69.2 | S2 | 250 and 350 | 6≤ IOP ≤21 and ≥20 % reduction | 48 | A:38.5 |
| B:70 | B:36/34 | B:62.3 | B:34.6 | |||||||
| Tesser R (2005) | Retro | <18y, concurrent primary or secondary IOL implantation | A:3 | ND | 7.6 | S2 | 250 and 350 | IOP ≤22 | 21 | A:35 ± 4.6 |
| B:6 | B:31.3 ± 0.8 | |||||||||
| Chung AN (2004) | Retro | >18y,concurrent Phaco and IOL implant | A:16 | 15/17 | 58 ± 16 | ND | 350 | 6≤ IOP ≤21 | 13 ± 5 | A:26.2 ± 13.4 |
| B:16 | B:29.7 ± 13.4 | |||||||||
| Syed HM (2004) | Case control | All ages, Baerveldt implantation were matched case by case with Ahmed valve implantation | A:32 | A:20/12 | A:58 ± 24 | Polypropylene | 350 | 5< IOP <22 and ≥30 % reduction | 8–16 | A:30.69 ± 10.28 |
| B:32 | B:13/19 | B:61 ± 23 | B:30.09 ± 9.17 | |||||||
| Wang JC (2004) | Retro | All ages | A:18 | A:10/8 | A:60.0 ± 18.2 | S2 | 250 | IOP <22 | A:22.2 ± 9.2 | A:43.7 ± 9.3 |
| B:24 | B:15/8 | B:48.1 ± 23.2 | B:22.8 ± 8.7 | B:40.1 ± 13.8 | ||||||
| Beck AD (2003) | Retro | <2y | A:32 | ND | 7mon ± 5.1 | S2 and S3 | 250 and 350 | IOP <23 | A:33.0 ± 25.5 | A:32.2 ± 7.0 |
| B:14 | B:24.9 ± 12.9 | B:33.5 ± 5.6 |
RCT: prospective randomized controlled trial; Retro: retrospective comparative controlled trial; ND: no details; IOL: Intraocular lens; Phaco: phacoemulsification; IOP: intra-ocular pressure; AGV (A): Ahmed glaucoma valve group; BGI (B): Baerveldt Glaucoma Implant group
*The study reported set several different IOP criteria (14 mmHg, 18 mmHg, and 21 mmHg). We adopted the criterion of 21 mmHg